Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N7N8 | ISIN: KYG4818G1010 | Ticker-Symbol: 6IB
Frankfurt
06.06.25 | 15:29
8,050 Euro
+1,90 % +0,150
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
INNOVENT BIOLOGICS INC Chart 1 Jahr
5-Tage-Chart
INNOVENT BIOLOGICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
8,0508,30017:27
8,0508,35017:27

Aktuelle News zur INNOVENT BIOLOGICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05:47G Sachs Elevates INNOVENT BIO TP to $74.95, Rating Buy1
INNOVENT BIOLOGICS Aktie jetzt für 0€ handeln
DoHutchmed China Ltd - HUTCHMED and Innovent Announce NDA Acceptance-
DoBOCI Elevates INNOVENT BIO TP to $82, Keeps Rating at Buy3
DoNew Drug Application for INNOVENT BIO's Sintilimab Combination with HUTCHMED's Fruquintinib Accepted in CN1
DoHUTCHMED Last Leaps ~5%, While INNOVENT BIO Falters; Application for Combination Therapy for RCC Accepted1
DoInnovent's IBI363 Receives Second NMPA Breakthrough Therapy Designation For Immuno-resistant SqNSCLC308BEIJING (dpa-AFX) - Innovent Biologics Inc. (IVBXF.OB) announced Wednesday that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted a...
► Artikel lesen
DoHUTCHMED (China) Limited: HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma2
DoINNOVENT BIO (01801): VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR SINTILIMAB COMBINATION ...2
MiLummus signs MoU with InnoVent for tire pyrolysis technology2
MiINNOVENT BIO Hyped Up 16%+; UBS Cites Firm Expecting Breakeven This Yr, Industry Top Pick Reiterated5
DiJPMorgan raises Innovent Biologics stock price target to HK$7410
DiJPMorgan erhöht Kursziel für Innovent Biologics auf 74 HK$5
DiJPM: TP Elevated to $74 on Encouraging Research Data of INNOVENT BIO (01801.HK) IBI363/IBI3431
Di2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors52SAN FRANCISCO and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
► Artikel lesen
MoINNOVENT BIO (01801): FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, JUNE 25, 20251
MoINNOVENT BIO (01801): NOTICE OF ANNUAL GENERAL MEETING-
MoINNOVENT BIO (01801): (1) PROPOSED GRANTING OF GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE NEW SHARES, (2) PROPOSED RE-ELECTION OF RETIRING DIRECTORS, ...1
29.05.Innovent Biologics: Innovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Response ...70SAN FRANCISCO and SUZHOU, China, May 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
► Artikel lesen
26.05.CICC Raises INNOVENT BIO TP to $69 as Colorectal Cancer Drug Data Beats Forecasts3
26.05.Innovent Biologics: Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)176SAN FRANCISCO and SUZHOU, China, May 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
► Artikel lesen
Weiter >>
86 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1